In the U.S., there is a nearly 40-year gap between average lifespan and healthy life expectancy. Many people are living longer, but spending more years managing fatigue, frailty, metabolic disease, cognitive decline, and loss of independence.
That challenge is what inspired XPRIZE Healthspan.
Key takeaways:
- AgelessRx was named a Top 40 semifinalist in the XPRIZE Healthspan competition.
- AgelessRx evaluated a multi-intervention longevity strategy in adults aged 60–80.
- Participants showed early improvements in sleep quality, mood, energy, immune function, and functional fitness.
- The treatment group demonstrated an estimated 2-year reversal in biological age using PhenoAge testing.
- No clinically significant adverse changes were observed across 39 safety markers during the pilot study.
- The findings support growing interest in personalized, multi-system approaches to healthy longevity.
What is healthspan?
Healthspan refers to the years of life spent in good health, free from major chronic disease, disability, and functional decline.
For most of modern history, medicine has focused on helping people live longer by treating disease once it appears. That has led to extraordinary progress for lifespan extension. Average lifespan has more than doubled over the last century, but healthy life expectancy, or healthspan, has not progressed at the same pace.
Many people now live into their 80s and 90s, but spend up to 50% of their life managing chronic disease, functional decline, pain, fatigue, and loss of independence.
Aging is the biggest risk factor for most major chronic diseases, increasing vulnerability to heart disease, cancer, Alzheimer’s, and frailty.
This is not simply because we get older as time passes. It is because the process of biological aging slowly erodes the systems that help the body repair, adapt, and recover.
Under the surface, aging changes how cells produce energy, clear waste, regulate inflammation, respond to stress, and communicate with one another. Over decades, these small shifts compound. The body becomes less resilient, damage accumulates, and essential systems lose function. This is how biological aging becomes disease.
XPRIZE Healthspan recruits top teams worldwide to develop strategies that target the biology of aging earlier, restoring function before decline becomes disease.
What Is XPRIZE Healthspan?
XPRIZE was created nearly three decades ago to incentivize breakthroughs in areas that could meaningfully change the future of humanity, from spaceflight to climate to human health. Its competitions are not built around incremental improvements. They are designed to push past known limits, accelerate bold ideas, and redefine what’s possible.
XPRIZE Healthspan applies that model to aging and longevity, and the benchmark is bold.
This seven-year, $101 million global competition challenges teams to develop therapeutic strategies that can restore muscle strength, cognitive performance, and immune health in generally healthy older adults by at least 10 years, with an aspirational goal of 20 years. And demonstrating those improvements within a one-year clinical trial.
In practical terms, that means taking a 60-year-old and functionally reversing aging to that of a 40-year-old across key systems tied to healthy aging.
AgelessRx was named one of just 40 semifinalists out of more than 500 applicants worldwide for a targeted, multi-intervention longevity strategy designed to address aging across multiple biological systems simultaneously.
In a 3-month, placebo-controlled pilot study of generally healthy adults aged 60-80, AgelessRx evaluated a multi-intervention longevity protocol designed to support brain, immune, metabolic, and muscle health together. Participants in the treatment group showed early signals of improvement in energy, mood, sleep quality, functional fitness, and immune function, along with an estimated 2-year reversal in biological age.
While these findings are still early, they point to an important shift: longevity medicine is moving beyond the search for a single “anti-aging” pill toward multi-intervention strategies that target aging across the body’s major systems to help restore function and strengthen resilience with age.
What is AgelessRx’s approach to reversing age-related decline?
Aging is not caused by one broken pathway.
It is a network problem. Different tissues age in different ways. The immune system becomes more inflammatory. Muscle loses its ability to adapt and regenerate. The brain becomes more vulnerable to metabolic stress, vascular changes, and degeneration. Mitochondria may become less efficient, and cellular repair pathways may slow down.
This is why a single intervention is unlikely to address the full complexity of aging.
Think of aging like maintaining a home. It is not enough to mop the floors. You need to take out the trash, change the air filters, fix the plumbing, and repair the roof. Each system has its own vulnerabilities, but they all affect the health of the whole structure.
The body works in a similar way. The organs are connected, but they do not all age identically. Restoring function may require a comprehensive, multi-system approach.
Our strategy is built around this systems-level view of aging. Rather than relying on a single tool, the approach combines evidence-based interventions targeting different biological drivers of age-related decline.
What interventions are included in AgelessRx’s XPRIZE Healthspan strategy?
Our pilot study’s strategy included a combination of prescription interventions and structured lifestyle programs selected to support key systems involved in muscle, brain, and immune aging:
Low-dose Rapamycin has been shown to promote cellular waste removal, support immune function, and extend lifespan across multiple species.
Low Dose Naltrexone is an anti-inflammatory intervention studied for autoimmune conditions and symptoms often associated with inflammation, including brain fog and pain.
Metformin is a metabolic intervention commonly used to lower blood sugar and improve insulin resistance, with evidence suggesting potential effects on mitochondrial function and cellular senescence.
NAD+ is a vital molecule involved in cellular energy production, repair, and resilience. NAD+ levels decline with age, which may contribute to fatigue, cognitive decline, and tissue degeneration. Boosting NAD+ replenishes a key factor that cells need to meet cellular energy demands, repair age-related damage, and buffer organs from the impact of daily stressors.
Longevity medicine should not separate therapeutics from lifestyle change. Resistance training remains one of the most well-validated interventions for preserving muscle, cognition, metabolism, mood, and immune health.
Mindfulness meditation and stress regulation have been shown to improve sleep, reduce inflammation, enhance immune function, and improve mental clarity.
The key is not simply combining more interventions. It is combining the right interventions with a clear biological rationale and regular monitoring.
What did AgelessRx find in the XPRIZE Healthspan semifinals?
In the semifinal stage, we conducted a 3-month, placebo-controlled study in 18 adults aged 60-80. The study focused on safety, feasibility, and early signals of benefit to inform the strategy for the finals.
The treatment group showed improvements across several domains tied to healthspan, including:
- Energy
- Mood
- Sleep quality
- Functional fitness
- Immune function
Participants also showed an estimated biological age reversal of approximately 2 years using the PhenoAge biological age test.
One major challenge in the field is that there is very little data on the safety and side effects of multi-intervention longevity strategies, especially those that include multiple prescription treatments.
Across 39 safety markers, no clinically significant adverse changes were observed in the treatment groups. Blood markers spanning liver, kidney, metabolic, and immune function remained stable, supporting the tolerability of the combination strategy.
Although the study was small, the signal is promising: measurable restoration of real-world function, reversal of biological age, and no major side effects observed across standard safety markers.
How multi-intervention strategies may transform longevity medicine
This is not a new idea in medicine. Multi-intervention strategies have been shown to lead to better outcomes across many age-related diseases.
Cardiovascular prevention may involve lipid-lowering therapy, blood pressure management, anti-inflammatory strategies, and aerobic exercise.
Diabetes care often combines multiple blood sugar medications, weight management protocols, and biomarker tracking.
Aging is much more complex than any single disease.
Yet much of longevity medicine has historically studied one intervention at a time. That approach is useful for understanding mechanisms and is often the best place to start, but it may underestimate what is possible when multiple systems are addressed together.
A multi-intervention strategy can target multiple aging pathways simultaneously. NAD+ may support metabolic signaling and mitochondrial energy production. Glutathione may help reduce oxidative stress and inflammatory tone. Sermorelin may support growth signaling and regeneration. When thoughtfully combined and monitored, these interventions may have the potential to restore function across systems and support long-term health.
How could this research eventually impact patient care?
For patients, the most exciting part of this work is not the XPRIZE Healthspan competition itself. It is what this research model could make possible.
If multi-intervention strategies continue to show strong safety signals and promise, longevity care could become more proactive, measurable, and impactful—built around personalized strategies rather than single interventions.
Clinicians may be able to identify patterns of decline earlier and intervene across the systems most relevant to each person.
That could mean using biomarkers to evaluate inflammation, metabolic health, mitochondrial function, immune function, and hormone patterns, then pairing that information with therapeutics and lifestyle strategies in a more structured way.
Instead of relying on a single intervention to recalibrate the whole system, the future of longevity care may involve protocols designed around an individual’s biology, goals, risks, and measurable outcomes.
This is the practical future we are helping build through our research efforts: longevity care that is personalized, data-driven, and focused on preserving function before decline becomes disease.
Beyond XPRIZE Healthspan
Being named a Top 40 semifinalist in XPRIZE Healthspan signals that our approach is being evaluated on a global stage alongside some of the most ambitious teams in longevity science.
It also reflects a broader shift in the field: longevity medicine is moving from preclinical research toward real-world applications, from isolated interventions toward systems biology, and from lifespan extension toward healthy longevity.
XPRIZE Healthspan is one milestone in a much larger research roadmap.
We are continuing to explore how multi-intervention strategies may help address age-related functional decline across multiple systems to support patients’ longevity goals. The results of our pilot study offer an early signal that this approach is worth studying more deeply. Whether we make the finals or not, evaluating multi-intervention strategies for longevity will be a part of our broader research efforts.
How Is AgelessRx helping shape the future of healthspan?
Our XPRIZE Healthspan work reflects our larger mission: to make evidence-based longevity care more accessible, measurable, clinically grounded, and impactful.
This research is not separate from our care model. It informs how longevity protocols are developed, how interventions are selected, how outcomes are measured, and how personalized strategies are built.
It also gives our users a window into the science happening behind the scenes: the research, testing, and clinical thinking needed to move longevity medicine from promising theory into practical care.
The future of healthy aging will not be built on a single pill or breakthrough. It will be built through better data, smarter protocols, and a deeper understanding of how multiple interventions work together across the body’s major systems.
At AgelessRx, we aren’t just following the future of longevity medicine; we are helping build it. Explore our clinician-guided longevity protocols and learn how research-backed, personalized care can help you take a more proactive approach to healthy aging.
Frequently asked questions
What is XPRIZE Healthspan?
XPRIZE Healthspan is a $101 million global competition focused on developing therapies that can restore muscle, brain, and immune function in older adults. Unlike traditional medicine, which often treats disease after it appears, XPRIZE Healthspan is focused on improving function earlier, before age-related decline turns into disease.
Why does XPRIZE Healthspan matter for longevity medicine?
XPRIZE Healthspan matters because it shifts the focus from simply living longer to living better. The competition is designed to accelerate research into interventions that may preserve strength, cognitive performance, immune health, and independence as people age.
What is AgelessRx’s XPRIZE Healthspan strategy?
AgelessRx is using a targeted, multi-intervention longevity strategy designed to address several biological drivers of aging at once. Instead of focusing on a single pathway, the approach combines prescription interventions and structured lifestyle programs to support muscle, brain, immune, metabolic, and cellular health.
Why are multi-intervention strategies important for healthy aging?
Aging is not caused by one pathway breaking down. It involves changes in inflammation, cellular repair, mitochondrial function, metabolism, immune signaling, muscle function, and brain health. Multi-intervention strategies may be more effective because they can target multiple systems simultaneously, which better reflects how aging occurs in the body.
What did AgelessRx find in the XPRIZE Healthspan semifinal study?
In AgelessRx’s 3-month, placebo-controlled semifinal study of adults aged 60–80, the treatment group showed early signals of improvement in energy, mood, sleep quality, functional fitness, and immune function. Participants also showed an estimated biological age reversal of approximately 2 years using the PhenoAge biological age test.
Was AgelessRx’s multi-intervention strategy safe?
In the semifinal study, no clinically significant adverse changes were observed across 39 safety markers. Blood markers related to liver, kidney, metabolic, and immune function remained stable, which supports the tolerability of the combination strategy in this small pilot study.
What is biological age reversal?
Biological age reversal refers to a measurable shift in biomarkers that estimate how old the body appears biologically, rather than chronologically. In essence, it represents a reversal in risk for disease and better systemic health. In the AgelessRx semifinal study, participants showed an estimated 2-year reversal in biological age using PhenoAge, a well-validated biological age test.
How could XPRIZE Healthspan research impact patient care?
This research may help make longevity care more personalized, proactive, and measurable. Instead of relying on a single intervention, future care models may use biomarkers, clinical monitoring, and multi-intervention protocols to target the systems most relevant to each person’s aging biology.
What makes AgelessRx’s longevity telemedicine service different?
AgelessRx combines clinical care, telemedicine infrastructure, real-world patient data, and rigorous research to develop personalized longevity strategies. The goal is to move longevity science from promising research into clinician-guided, measurable care.
—
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.